Sökning: WFRF:(Robertson Christine M.)
> (2020-2022) >
Markers of steroid ...
-
Campbell, ChristineFrontier Science (Scotland) Ltd
(författare)
Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance
- Artikel/kapitelEngelska2020
Förlag, utgivningsår, omfång ...
-
2020-10
-
AME Publishing Company,2020
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:c5ad83f4-0cc9-4ce1-81ac-33009503a6d5
-
https://lup.lub.lu.se/record/c5ad83f4-0cc9-4ce1-81ac-33009503a6d5URI
-
https://doi.org/10.21037/tbcr-20-31DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
Background: It remains clinically important to identify ER positive breast cancers likely to respond to tamoxifen (TAM) and so we aimed to select a group of biomarkers able to predict response. We also assessed whether data from different sample types [tumor microarrays (TMAs) and core biopsies] or tumor sites could be combined for biomarker studies.Methods: A total of 123 endocrine treatment naïve patients with known ER and HER2 status treated with TAM had paraffin-embedded tumor tissue available either as TMAs (n=102) or core biopsies (n=21). TMA cores were collected from three different tumor sites, two central and one peripheral. Ten biomarkers were evaluated by immunohistochemistry, for % positivity and/or H-Score, comprising: ER, HER2, Ki-67, phosphorylated forms of ER (Ser118), IGF1R, PRAS40, Akt & MAPK (ERK1/2), and PTEN & androgen receptor expression (AR). Each tumor was analysed for Akt1 E17K somatic mutation using BEAMing technology. Patient outcome was assessed by clinical benefit (CB) rate & survival analyses [time to progression (TTP) and time to death (TTD)].Results: There was no significant difference in % positivity or H-Score between central & peripheral tumor sites for all biomarkers examined. After False Discovery Rate (FDR) correction differences (P<0.05) were observed between the two central samples only for HER2 & pER118 and pPRAS40. However, differences in biomarker expression were common between core biopsies and TMAs. Only 2/123 (1.6%) tumors had Akt1 E17K mutations. Univariate and multivariate analyses identified that lower levels of PTEN and higher levels of Ki-67 (% positivity) were predictive of poor outcome (TTP & TTD) following TAM. Higher ER. lower Ki-67 and AR/ER ratio <2 predicted increased CB rate.Conclusions: There were few differences in marker expression between TMAs from different intra-tumoral sites. More marked differences between TMAs and core biopsies suggest caution if combining such datasets. Loss of PTEN, a key regulator of the PI3K/Akt pathway, was the only RTK/kinase signaling biomarker related to poorer clinical outcome. PTEN along with ER & lower Ki-67 proved the most predictive markers for better outcome (TTP & TTD and/or CBR) following TAM treatment.Keywords: ER+ breast cancer; Akt pathway; tamoxifen
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Mathew, JohnPeterborough City Hospital
(författare)
-
Ellis, Ian O.University of Nottingham
(författare)
-
Bradbury, IanFrontier Science (Scotland) Ltd
(författare)
-
Borgquist, SigneAarhus University(Swepub:lu)ront-sbo
(författare)
-
Elebro, KarinLund University,Lunds universitet,Kirurgi,Forskargrupper vid Lunds universitet,Bröstcancer - prevention & intervention,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröstcancer,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Surgery,Lund University Research Groups,Breast cancer prevention & intervention,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breastcancer,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-kee
(författare)
-
Green, Andrew R.University of Nottingham
(författare)
-
Finlay, PaulineCardiff University
(författare)
-
Gee, Julia M. W.Cardiff University
(författare)
-
Robertson, John F. R.University of Nottingham
(författare)
-
Frontier Science (Scotland) LtdPeterborough City Hospital
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Translational Breast Cancer Research: AME Publishing Company12218-6778
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Campbell, Christ ...
-
Mathew, John
-
Ellis, Ian O.
-
Bradbury, Ian
-
Borgquist, Signe
-
Elebro, Karin
-
visa fler...
-
Green, Andrew R.
-
Finlay, Pauline
-
Gee, Julia M. W.
-
Robertson, John ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Translational Br ...
- Av lärosätet
-
Lunds universitet